Resources for Researchers

NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.

Showing results filtered by:
Clear All
Ebola and Marburg
Emerging Infectious Diseases/Pathogens
Therapeutics

15 Results

Developing, characterizing, and refining animal models are key to advancing medical countermeasures for high-consequence pathogens.

Artificial intelligence (AI), in its many forms, is applied to infectious disease research at the IRF-Frederick. Primarily focused on medical imaging of preclinical models, state of the art methods are developed, applied to ongoing research and translated to human studies of disease.

The BEI Resources Repository is a central repository that supplies organisms and reagents to the broad community of microbiology and infectious diseases researchers. Materials are available through an online catalog.

The National Emerging Infectious Diseases Laboratories (NEIDL) is one of two National Biocontainment Laboratories constructed under a grant from the National Institute of Allergy and Infectious Diseases.

As one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the Galveston National Laboratory (GNL) enables progress in our understanding of the fundamental mechanisms underlying the spread of infectious diseases and the pathogenesis of the diseases they cause.

The Clinical Studies Support Team (CSST) is a deployable team with the primary objective of developing and fostering overseas relationships through the support of research studies and clinical trials involving pathogens of high consequence.

The Early Phase Clinical Trial Units (EPCTUs) support the design, development, implementation, and conduct of Phase 0 to Phase 2 clinical trials, including proof-of-concept studies in healthy, special, and disease-specific populations, carried out in an expeditious and efficient manner, aided by bioanalysis when necessary, against viral, bacterial, parasitic, and fungal pathogens and emerging a

In vivo imaging is gaining increasing interest for the characterization of infectious diseases, including the ones caused by high-consequence pathogens.

The immunology laboratory at the Integrated Research Facility at Fort Detrick (IRF-Frederick) offers a variety of capabilities to interrogate the immune responses against pathogens requiring maximum containment.

The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical specimens.

The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins.

Note: Devices are excluded.

Part of the Therapeutic Development Services program.

The pathology department and histology laboratory at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) work together to develop and use established animal models of high-consequence emerging human viruses to study disease pathogenesis and facilitate countermeasure development under The Animal Rule.

This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.

The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.

The virology team at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) has extensive expertise working with a range of high‑consequence viral pathogens. Studies focus on gaining a deeper understanding of viral pathogenesis and advancing clinical approaches to assist in managing diseases.

The team leverages fundamental methodologies, such as: